Sunday, August 10, 2025

MindMed Begins Study On LSD Neutralizer Technology

MindMed (NEO: MMED) this morning announced that it has begun a study on what it refers to as “LSD neutralizer technology.” The tech is intended to stop the effects of an LSD trip while a patient is undergoing a therapy session.

The study is being conducted with the University Hospital Basel’s Liechti Lab via a phase one trial, which will evaluate the effect of ketanserin on the response to LSD after LSD administration. The project is associated with the firms LSD therapy studies referred to as Project Lucy, with the company looking to improve the therapy session with additional features to create a better patient experience.

Expected to be completed by year end, the company is effectively looking to evaluate the compound for use as an “emergency-off” switch for psychedelic assisted therapies. The tech, if successful, is ideal for when a “bad trip” occurs for the patient, or the session is not going as intended.

The study will work under the premise that the administration of 40mg of ketanserin one hour after taking LSD will significantly shorten and reduce the effects of LSD, when compared to LSD alone and a placebo. The compound is currently marketed as an antihypertensive agent.

Mindmed last traded at $5.31 on the NEO.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

New Found Gold: The Queensway PEA

Newmont Q2 Earnings: Setting The Tone For This Earnings Cycle

Highest Grade Antimony Mine in the World!? | James Atkinson – Antimony Resources

Recommended

Nova Scotia Bans Forest Access to Prevent Wildfires

Cardiol Therapeutics Releases Positive Topline Results From Phase II Clinical Trial

Related News

Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles

It seems that after selling $24.7 million in company stock, JR Rahn is looking to...

Wednesday, June 9, 2021, 07:50:06 AM

Mind Medicine Applies To List On The Nasdaq

Mind Medicine (NEO: MMED) this morning announced that it has submitted an application to uplist...

Monday, September 21, 2020, 07:53:31 AM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Mind Medicine Announces $50 Million Bought Deal Financing Days After Raising $34.5 Million

Mind Medicine (NEO: MMED) is raising even more cash. The company this evening announced that...

Monday, December 14, 2020, 08:43:58 PM

Mind Medicine Boasts Current Cash Position Of US$161 Million

Mind Medicine (NEO: MMED) this morning released its fiscal year 2020 financial results. Given that...

Tuesday, March 30, 2021, 08:19:57 AM